Blau Farmacêutica: Q1 2025 saw 4% revenue growth, 50% higher net income, and strong private hospital performance

About this update from Blau Farmaceutica Sa

Revenue grew 4% year-over-year in Q1 2025, with strong 15% growth in the private hospital segment and a 50% increase in net income. Investments in biotechnology and new product launches support a robust outlook, despite temporary impacts from regulatory and supply chain transitions.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Blau Farmaceutica Sa